Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galectin Therapeutics Inc
GALT | US
2.37
USD-0.08
-3.27%
GALT | US
Loading StockChartView...
About Galectin Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
23/04/2026
Close
2.37
Open
2.43
High
2.50
Low
2.36
Galectin Therapeutics Inc. a clinical stage biopharmaceutical company engages in the research and development of therapies for fibrotic cancer and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis as well as for the treatment of cancer. The company through its Galectin Sciences LLC which is a collaborative joint venture co-owned by SBH Sciences Inc. to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross Georgia.
View LessGALT | US
Risk
101.3
Sharpe
0.64
Luna's Score
40/100
Recommendation
Sell
Luna says (GALT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
109.1%1 month
101.3%3 months
84.1%6 months
91.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
207.70
Debt to equity
-1.14
Debt to assets
3.38
Ent. to EBITDA
-4.04
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
147.60M
MarketCap(USD)
147.60M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-3.73K
Short ratio
43.75
Short perc.
17.94
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.37
Range1M
0.84
Range3M
1.38
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.47
Price X volume
381.29K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.04 | 24.85 | Cheaper |
| Ent. to Revenue | - | 361.91 | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | 207.70 | 13.15 | Expensive |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 84.05 | 65.24 | Riskier |
| Debt to Equity | -1.14 | -1.88 | Expensive |
| Debt to Assets | 3.38 | 0.48 | Expensive |
| Market Cap | 147.60M | 3.71B | Emerging |
